-
Sector Analysis
NewSweden Cards and Payments – Opportunities and Risks to 2028
GlobalData’s ‘Sweden Cards and Payments: Opportunities and Risks to 2027' report provides detailed analysis of market trends in the Swedish cards and payments industry. It provides values and volumes for a number of key performance indicators in the industry, including cash, credit transfer, cards, direct debits, and cheques during the review-period (2019–23e). The report also analyzes various payment card markets operating in the industry and provides detailed information on the number of cards in circulation, transaction values and volumes during...
-
Product Insights
Likelihood of Approval Analysis for Autism Spectrum Disorder (ASD)
Overview How likely is it that the drugs in Autism Spectrum Disorder (ASD) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Autism Spectrum Disorder (ASD) Overview Autism Spectrum Disorder (ASD) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Solid Tumor Drug Details: Disitamab vedotin (Aidexi)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Bladder Cancer Drug Details: Disitamab vedotin (Aidexi)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Salivary Gland Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Salivary Gland Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Salivary Gland Cancer Drug Details: Disitamab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Esophageal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Esophageal Cancer Drug Details: Disitamab vedotin (Aidexi) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Metastatic Colorectal Cancer Drug Details: Disitamab vedotin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Metastatic Transitional (Urothelial) Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Metastatic Transitional (Urothelial) Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Metastatic Transitional (Urothelial) Tract...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Head And Neck...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Cervical Cancer Drug Details: Disitamab vedotin (Aidexi)...